bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.07.12.499784

White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer's disease: evidence from data-driven disease progression modelling

Parker, C. S.·Weston, P. S.·Zhang, H.·Oxtoby, N. P.
View original source ↗Export metadata ↓

Abstract

Sequencing the regional progression of neurodegeneration in Alzheimers disease (AD) informs disease mechanisms and facilitates identification and staging of individuals at greatest risk of imminent cognitive decline, which may aid the development of early therapeutic interventions. Previous attempts to sequence neurodegeneration have analysed measures of regional volume and identified the initial sites of atrophy. However, focal microstructural alterations in white matter have also been reported in early AD. Yet, the temporal ordering of abnormality in measures of white matter microstructure relative to grey matter volume has not been established. In this study we used event-based modelling of disease progression (EBM) to provide a data-driven evaluation of the temporal sequence of abnormality in markers of white matter microstructure relative to grey matter volume. Regional microstructural metrics derived from diffusion tensor imaging (DTI) and regional volumes from Freesurfer cortical parcellation were obtained from the Alzheimers disease Neuroimaging Initiative (ADNI) database for 441 amyloid-positive participants (81 AD-dementia, 159 mild cognitive impairment, 201 cognitively normal). The estimated sequence shows a series of abnormalities in markers of white matter microstructure, followed by sequential grey matter volumetric decline, with no overlap between the two. Analysis of positional variance and cross-validation supports the robustness of our findings. These results provide the first data-driven evidence that markers of white matter microstructural degeneration precede those of cortical volumetric decline in the AD cascade. This prompts a re-evaluation of the view that regional volumetric decline can be used to characterise the very earliest stages of AD neurodegeneration. Instead, we suggest that white matter microstructural markers provide an earlier window into AD neurodegeneration. An early staging system of AD neurodegeneration based on measures of brain microstructure may find application in selecting AD subjects with early but minimal brain damage for clinical trials that aim to prevent cognitive decline.

Explore related subjects

neurosciencePreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Parker, C. S., Weston, P. S., Zhang, H., Oxtoby, N. P.. 2022-07-14. White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer's disease: evidence from data-driven disease progression modelling. https://doi.org/10.1101/2022.07.12.499784

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗
bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗
bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗